drugset / Trial / NCT02278055
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Phase 2
Completed
29 enrolled
Memorial Sloan Kettering Cancer Center
New York Presbyterian Hospital · collabUniversity of North Carolina · collab
NaSingle-groupOpen-labelSupportive care
Summary
The purpose of this study is to find out if Radium-223 is effective in reducing cancer pain within 12 weeks of treatment. In order to see if Radium-223 is effective, the patient's level of pain will be followed throughout the study.
Timeline
- Start
- 2014-10-08
- Primary completion
- 2022-02-02
- Completion
- 2022-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radium-223 dichloride | Other / unclassified | 0.055 mbq/kg | Intravenous |